ABSTRACT
Introduction
DNA crosslinking agents represent a structurally diverse group of compounds including sulphur and nitrogen mustard derivatives, nitrosoureas, and antibiotics such as mitomycin C (Lawley and Phillips, 1996; Noll et aI., 2006) . The critical lesion consists of a covalent bond between complementary DNA strands, which prevents strand separation leading to transcription and replication blockage and, in many cases, to cell death (Kee and D'Andrea. 2010; Noll et al.. 2006;  Dronkert and Kanaar. 2001;  Lawley and Phillips, 1996) . Due to their exquisite toxicity. DNA crosslinking agents have been used for decades as cytostatic drugs. The first crosslinking agent to be synthesized was SM. a chemical warfare agent that was first used during the World War I. Later on. controlled medical application ofSM for cancer treatment was investigated but failed because of difficulties in handling and the high reactivity of the compound. which rendered systemic application impossible. However. in subsequent years less reactive derivatives of nitrogen mustard were synthesized. The agents induce formation of several different adducts within DNA. the majority of which being monoadducts resulting from of a single substitution event. A small proportion of monoadducts are engaged in a second reaction producing DNA crosslinks. Although interstrand crosslinks represent only a minority of DNA adducts. they are thought to be critical for cell death induction. Their formation. persistence and repair clearly correlate with cytotoxicity in vitro both in prokaryotic and eukaryotic cells (Noll et al.. 2006;  Dronkert and Kanaar. 2001; McHugh et al.. 2001) . Importantly. a positive correlation was found between patient survival and level ofDNA crosslinks in vivo. After high-dose melphalan treatment patients with increased DNA adducts formation and slower repair showed improved response and progression-free survival (Souliotis et al.. 2003) . Furthermore. it was shown that ex vivo DNA damage in PBMC reflects the in vivo situation (Spanswick et al.. 2002) . Therefore the amount of DNA crosslinks assessed ex vivo in PBMC might be used as predictive biomarker for hi gh-dose melphalan treatment in multiple myeloma patients (Dimopoulos et al.. 2007) . Additionally. in case of cyclophosphamide and ifosfamide. the evaluation of crosslink formation in PBMC of patients yields information on metabolic drug activation. Both are administered as inactive pro-drugs and undergo metabolic activation in the liver, resulting in the formation of reactive metabolites, i.e. 4-hydroxycyclophosphamide and 4-hydroxy-ifosfamide. The monitoring of crosslink formation could therefore serve as an indicator for the effective dose reached in the patient (Hartley et aI., 1999) .
Although the assessment of DNA cross links might be highly beneficial for modern, individualized therapy this issue has been addressed only in a very limited number of studies. One of the reasons might be the lack of established, suitable methodology. So far, measurement of DNA crosslinks has been performed by alkaline filter elution, agarose gel based methods or reverse comet assay (Pfuhler and Wolf, 1996; Souliotis et aI., 2003) . While the first two require a large number of cells, they are not easily adapted for in vivo studies and may be problematic regarding patients' health and ethical considerations. The most suitable assay for this purpose appeared to be the reverse comet assay, due to the modest requirements for biological material. However, the standardization of comet assay is not an easy task due to problems with objectivity during evaluation. Variation in sample analysis was observed within one sample evaluated by different laboratory staff (Forchhammer et aI., 2008) . Consequently, despite years of investigation, only the alkaline version of the comet assay was recognised by the Organisation for Economic Co-operation and Development (OECD) and the appropriate guideline is in preparation (BrendlerSchwaab et aI., 2005) .
The aim of the present study was to develop a high-throughput, automated, standardized assay, operating on human PBMC for measurement of DNA crosslinks. The original version of the fluorimetric alkaline DNA unwinding assay (FADU assay) was described by Birnboim and Jevcak (1981) for detection of "'I-ray induced DNA strand breaks in human PBMC. We have recently established an automated FADU for strand breaks detection. While its sensitivity of is comparable to the comet assay and alkaline filter elution, the simple and fast protocol and the robustness of the assay is an advantage (Moreno-Villanueva et aI., 2009). The assay is based on the assumption that each strand break serves as an unwinding point during the alkaline denaturation of chromosomal DNA in the cell lysate. Thus at defined temperature and pH conditions the extent of DNA strand separation is dependent on number of strand breaks and can be standardized with respect to the initial level of induced strand breaks by use of ionizing radiation, which produces known numbers of DNA strand breaks per cell. The unwinding is quantified by means of a fluorescence dye that binds exclusively to the DNA that remains double stranded after completion of the alkali incubation. The manually operated version of the FADU assay was successfully applied for measurement of DNA strand breaks in different cell types and organelles upon irradiation and chemical treatment (Baumstark-Khan et aI., 1992 Roos et aI., 2000) . Surprisingly, in contrast to the comet assay it has not been adopted by many laboratories. Our automated, microtiter-based assay format seems to be an ideal candidate for standardized, large-scale biomonitoring studies. Here, we describe the automated reverse FADU assay optimized for assessment of DNA interstrand crosslinks in human PBMC, including optimized procedures for preparation, storage and shipment of samples.
Materials and methods

. Isolation of peripheral blood monDnuclear cells (PBMC)
Peripheral venous blood was obtained from healthy volunteers and samples were anonymized. Ethical approval had been obtained by the University of Konstanz Ethics Committee. PBMC were isolated by Biocoll (Biochrom AG, Berlin, Germany) gradient centrifugation according to manufacturer's protocol. PBMC were maintained in RPMI 1640 medium (Invitrogen, Karlsruhe, Germany) supplemented with 10% FCS (Biochrom AG. Berlin, Germany), 100 U/ml penicillin and 100 f!..g/ml streptomycin (Invitrogen, Karlsruhe, Germany) at a cell density of 10 6 cells/ml in a humidified atmosphere at 37°C and 5% C02.
In order to stimulate T lymphocytes for proliferation, freshly isolated PBMC were incubated with 5 f!..g/ml PHA-L (Roche, Penzbe rg, Germany) for 48 h under standard culture conditions. The cell cycle distribution was analyzed by flow cytometry after staining with propidium iodide by using an established protocol (Roos et aI., 2004) . Forty-eight hours after addition of PHA-L the population reached asynchronous growth and all cell cycle phases were represented (data not shown). PHA-L was present in culture medium during the whole duration of the experiments, inclusive treatment with melphalan and post-incubation.
ISDlatiDn Df human leukDcytes by erythrocyte lysis
IsolatiDn of leukocytes by erythrocyte lysis was performed by using an erythrocyte lysis kit (R&D Systems, Minneapolis, MN) according to manufacturer's protocol.
Cell treatment with DNA-crosslin king agents
Mitomycin C, melphalan and CEES were purchased from Sigma-Aldrich GmbH (Daisenhofen, Germany). Mitomycin C was dissolved in water (final concentration 500 f!..g/ml) and stored at 4°C for up to 7 days. Melphalan solution (10 mg/ml in 95%EtOH/0.5%HCl) was prepared directly before use. Mutagen treatment was performed by adding aliquots of drug serial dilutions to cells in complete culture medium. PBMC were incubated in a cell culture incubator for 60 min, collected by centrifugation and the mutagen-containing medium was carefully removed. Cells were washed with PBS, resuspended in culture medium and cultured under standard conditions. SM was purchased from TNO (Rijswijk, The Netherlands). SM was initially dissolved in ethanol and then diluted to final concentration in Eagle Minimal Essential Medium without foetal calf serum immediately prior to cell treatment. Mutagen treatment was performed by adding aliquots of drug serial dilutions to cells in Minimal Essential Medium without calf serum. PBMC were incubated in a safety hood at room temperature for 30 min, collected by centrifugation and the mutagen-containing medium was carefully removed. Cells were washed with PBS, resuspended in culture medium and cultured under standard conditions.
CryD-preservation of cells
PBMC (10 6 cells/well) were harvested by centrifugation (260 x g, 5 min at 4°C) and resuspended in pre-chilled culture medium supplemented with 10% DMSO. Cells were immediately transferred into cryo-tubes placed on ice and frozen down slowly at -80°C in cryo-container filled with 100% 2-propanol. For long-term storage wells were transferred to liquid nitrogen the next day.
PBMC were thawed in a water bath at 37 D C for 1 min. The cell suspension was combined with 5 ml culture medium and pelleted by centrifugation (200 x g, 5 min at 4 ' C). PBMC were washed with 5 ml PBS and immediately analyzed by automated FADU assay.
5. Automated FADU assay
The protocol of the automated FADU has been published recently (Moreno-Villanueva et at.. 2009 ). Briefly, PBMC were resuspended in suspension buffer (10 mM Na-phosphate buffer, pH 7.4; 0.25 M meso-inositol ; 1 mM MgCI2) at the final concentration of lOs cells/ml. Leukocytes derived from 100 ILl whole-blood samples were resuspended in 2 ml of suspension buffer. For analysis of DNA strand breaks, 70 ILl cell suspension was transferred on ice into 96-well plates. For reverse FADU assay cells were additionally X-irradiated on ice with a dose of 25 Gy. The FADU assay is fully automated and all pippeting steps are performed by a liquid handling device Genesis RSP 100 (Tecan AG, Hombrechtikon; Switzerland). Seventy ILl lysis buffer (9 M Urea, 10 mM NaOH, 2.5 mM l ,2-cyclohexanedinitrilotetraacetic acid, 0.1 % 50S) was added at rate of 150 ILI/s and samples were incubated for 12 min at O°c. Pre-chilled alkaline buffer (42.5% lysis buffer, 0.2 M NaOH) was overlaid on top of the cell lysate at a rate of 10 ILI/s. Alkaline unwinding was performed at 30 "C for 60 min, then 140 ILl neutralization buffer ( 1 M glucose, 14 mM ~-mercaptoethanol) was added at a rate of200 ILI/s. Fo ll owing incubation at 22°C for 30 min, 156ILI SybrGreen solution (1 :8333 v/v in H20; MoBiTec, Giittingen, Germany) was added. Samples were mixed by automatic pipetting up and down. Fluorescence was measured in a 96-well-plate reader by excitation at 492 nm and emission at 520 nm. For each sample an internal control of DNA content was incorporated without alkaline unwinding process. Here the unwinding was prevented by addition of neutralization buffer to samples prior to the addition of alkaline buffer.
The ratio of double-stranded DNA was calculated as follows: 55 strand breaks. The principle of reverse FADU assay is analogous to the reverse comet assay and assumes that the alkaline unwinding is blocked at the sites of covalent bond between complementary DNA strands, i.e. ICL. Indeed, the measurement of DNA crosslinks can be performed indirectly by administering high-dose irradiation in order to induce large numbers of DNA strand breaks, causing massive alkali unwinding. If crosslinks are present, however, the unwinding would be decreased in comparison to the cells treated with irradiation only. Based on this rationale, we set up a reverse FADU assay based on a previously optimized automated protocol designed for detection of DNA strand breaks in human PBMC upon ionizing radiation (Moreno-Villanueva et aL. 2009 ). In preliminary studies to determine the optimal conditions of DNA unwinding and treatment with DNA break inducing agent, human PBMC were treated with melphalan for 24 h in a dose dependent manner. Melphalan belongs to the group of nitrogen mustard derived cytostatics, but in contrast to the more frequently used cyclophosphamide does not require metabolic activation (Colvin and Quong, 2002 
Comet assay
Cells were protected from sunlight during the whole experimental procedure in order to avoid additional DNA damage. After exposure of PBMC to various concentrations of melphalan or SM, viability of cells was determined by trypan blue exclusion and was found to be greater than 97%. Twenty ILl of the cell suspension was combined with 200 ILl low-melting agarose at a temperature of 37°C. 100 ILl of this mixture was transferred to agarose-coated slides and embedded in another layer of low-melting agarose. For reversed comet assay 20 ILl of the cell suspension was incubated with 0.002% H202 for 10 min at 4 °C and then combined with 200 ILl low-melting agarose and embedded on agarose coated slides. The slides were placed in cold (4°C) lysis buffer for 60 min. To unwind the DNA, the slides were placed in an alkali solu tion for 30 min and then subjected to electrophoresis (1 V/cm, 30 min) in an alkaline buffer (pH >13). After rinsing in distilled water, they were fixed with methanol at -20°C for 10 min. Slides were stained with ethidium bromide and measurements were done by means of a fluorescence microscope and "Komet 5.5" software (Kinetic Imaging Ltd.). 50 cells per slide were analyzed, thus yielding 100 data sets for each concentration (double determination).
Statistical analysis
Data analysis was performed by means of GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CAl software.
Results
Adaptation of FADU assay for detection of DNA interstrand crosslinks
The FADU assay is based on the direct relationship between the extent of alkali-induced DNA unwinding and number of DNA (data not shown). Lower irradiation doses had a negative impact on detection of melphalan cross links. Variation of DNA unwinding conditions, particularly temperature and time, did not improve the detection level for melphalan crosslinks (data not shown). Thus the reverse FADU protocol included X-irradiation with 25 Gy and alkaline unwinding at 30°C for 60 min, as described in Section 2.5.
Determination of detection limit of FADU assay for different DNA crosslinking agents
To validate the protocol for the reverse FADU assay and determine the detection limit for DNA crosslinks, DNA damage was measured upon pulse treatment with melphalan and two further compounds, i.e. mitomycin C and SM, in dose-dependent manner (Fig. 1) . For each compound the time point of maximal crosslink induction within the cell was chosen, which was directly after treatment for mi tomycin C or SM and 14 h after treatment with melphalan. The induction of crosslinks was manifested by an increase in double-stranded DNA after treatment with crosslinking agents in comparison to untreated but irradiated samples. In all cases, a dose-dependent induction of DNA crosslinks was observed (Fig. 1, left panel) . The lowest dose after which DNA crosslinks were detected was 5 ILg/ml mitomycin C, 5 ILg/ml melphalan and 3ILM SM, respectively (P< 0.001; Dunnett's Multiple Comparison PostTest). Noteworthy are the extremely small standard deviations and high reproducibility of experiments as a result of automation.
To evaluate the specificity of the reversed FADU assay for DNA crosslinks, we used 2-chloroethyl ethyl sulphide (CEES), which is a monofunctional sulphur mustard analogue. In the dose range up to 500 ILM CEES the fluorescence signal was identical to the control. This confirms that the increase in fluorescence of samples treated with the three other compounds is due to their crosslinking activity.
The FADU assay was performed simultaneously as direct and reverse assay (to assess DNA strand breaks and DNA cross links, respectively) in order to obtain maximal information on induced DNA damage within the same experiment. This does not lengthen the procedure or increase expenses. Among the crosslinking agents tested, only melphalan led to formation of DNA strand breaks, as did the monofunctional agent CEES (Fig. 1. right panel) . The melphalan-induced breaks might represent intermediates of nucleotide-excision or crosslink repair. However, at the later time point of 14 h after treatment apoptotic DNA cleavage cannot be excluded, Mitomycin C and SM did not induce any detectable DNA strand breaks. and the amount of doubl e stranded DNA remained at control level. This led us to assume that the reverse FADU assay In each experiment 100 cells were scored. White columns. DNA strand breaks; black columns.ICL. Each data set was compared to control using 1-way ANOVA with Dunnetrs Post Test ('significant vs. H20 2 control. #significant vs. untreated control.
P<0.05).
is not influenced by putative protein-DNA cross links. Otherwise a dose-dependent increase in double-stranded DNA over the control level in the direct FADU assay might be expected.
Direct comparison of FADU assay with reversed comet assay
To directly compare the sens itivity of the reverse FADU assay with previously described methods for ICLdetection. we performed the reverse comet assay (Fig. 2) . The reverse comet assay is currently the most frequently used method for the detection of DNA crosslinks. PBMC of different donors were treated with melphalan and SM as described above for the reverse FADU assay. The detection of DNA crosslinks was based on reduction of olive ta il moment (OTM) by the agents after induction of strand breaks with high dose of hydrogen peroxide. Our data show that the sensitivity of comet assay for detection of DNA crosslinks was comparable to that of the automated FADU assay. DNA crosslinks were detected in human PBMC after treatment with 1 IJ.M SM (P < 0.05. Dunnett's Multiple Comparison Post Test) (Fig. 2) . On the other hand. the DNA crosslinks detected in melphalan-treated PBMC did not reach statistical significance. The induction of DNA crosslinks by either compound was dose-dependent. as was the case with the reverse FADU assay. In contrast. strand break induction was elevated after treatment with the agents but this did not correlate with the dose applied. 
Impact of proliferation on results from reversed FADU assay
In the experiments described above. we have shown that the reverse FADU assay is suitable for the assessment of DNA interstrand cross links in human PBMC. The next question we addressed was if the FADU assay can also be applied for proliferating cells. Furthermore. we wanted to know if not only induction of crosslinks but also repair processes cou ld be monitored by FADU. Thus. DNA crosslinks and strand breaks were followed up in time-course experiments after treatment with 10 IJ.g/ml melphalan in res ting human PBMC and proliferating human T lymphocytes (Fig. 3) . Our data show that the acquisition of DNA damage was not impaired by proliferation. As a matter of fact. the induction of crosslinks and their repair was even more pronounced in proliferating lymphocytes than in PBMC. This might be due to relatively higher amount of euchromatin in proliferating cells compared to Go cells or higher cellular uptake of the drug. The inco rporation of crosslinks in proliferating cells was observed already within the first hour after treatment and reached a maximum by 2 h after treatment. while in resting cells at this time point crosslink induction was noticed and only increased with time to reach a maximum by 14 h after treatment. Within both cell types the repair process was observed starting at 18 h after treatment. Once again DNA repair was more effective in proliferating cells. Interestingly strand break induction appeared to be independent of proliferation status and was observed 14 h after treatment. Our data reveal that the reverse FADU assay detects with high sensitivity DNA crosslinks both in resting and proliferating cells. It is also a convenient method for assessment of DNA repair and differences in DNA damage different cell types.
Detection of crosslinks in whole blood samples
As the reverse FADU assay was primarily developed for highthroughput applications such as epidemiological and cl inical studies. it was important to determine the minimal sample volume necessary and to define optima l conditions for storage and shipment of samples between laboratories. Especially in case of cancer patients. there is a strong pressure to minimize the volume of blood to be sampled. in order to avoid the risk of compromising the patient's health even further. A great reduction in the blood volume required was ach ieved by using a protocol of erythrocyte lysis instead of density gradient centrifugation. and as little as 100 IJ.I of blood proved sufficient for the analysis (Fig. 4) . Comparison of human leukocyte preparation with PBMC showed that there was no difference in the detection of DNA crosslinks or in DNA strand breaks upon melphalan treatment of the cells ex vivo.
Assessment of DNA crosslinks by FADU assay in cryopreserved samples
In the context of epidemiological studies. sample collection often takes place at distant geographic locations. thus necessitating implementation of appropriate cell preservation and shipment protocols. To check if cryopreservation of the samples has an impact on the results from the reverse FADU. we compared the crosslinks leve l in human PBMC 14 h after treatment with melphalan processed immediately with samples that were cryopreserved by standard cell culture procedure and stored in liquid nitrogen for one month (Fig. 5) . Our data revealed that cryopreservation and liquid nitrogen storage had no influence on the detection of DNA crosslinks. However. the measurement of DNA strand breaks could not be perform ed reliably with thawed sa mples. The thawing process was critical for cells. and we observed that additional breaks appeared. which led to overestimation of DNA damage in some cases and to great variation between experiments. 
Validation of FADU assay with coded samples
All the above data support the idea that the ( Melphalan [lJg/mq below 100 IJ..M, th us mimicking in vivo exposure levels that would not necessari ly lead to characteristic acute symptoms including skin blisters. The samples were analyzed by reverse FADU assay and data were evaluated statistically by comparison with a previously established concentration-response curve (Fig. 1) . After breaking the code, our data showed that we have been able to distinguish samples exposed to doses higher or equal to our detection limit of 3 IJ..M ("victims") from controls with 100% accuracy (Table 1) . In some cases the SM concentration was underestimated but alto- . FrequencyoflCLafter melphalan treatment in human PBMC directly analyzed by FADU assay and after cryopreservation. PBMC were trea ted with melphalan for 60 min. washed with PBS and allowed to recover in fresh medium for 14 h. PBMC were harvested and split into three aliquots. Aliquot 1 was analyzed directly by FADU assay. Aliquots 2 and 3 were cryopreserved and analyzed by FADU assay after storage in -80 "C for 1 w eek and 1 month. respectively. Each column represents mean value s ± SEM from 4 independent experiments with 4 replicates (n ~ 4). Data sets were compared using 2-way ANOVA (P<0.05). gether our study proves the high accuracy and reproducibility of FADU data.
Discussion
The present paper is the first description of the use of the reverse FADU assay for the assessment of DNA interstrand crosslinks. The assay was previously applied for detection of DNA strand breaks but despite many advantages it has never reached the sa me popularity as the comet assay. The comet assay and also alkaline elution. however. are methods that are time-consuming and allow processing of only a limited sample number. The assessment of ICL would be of particular interest in cancer therapy and in personalized risk 59 assessment. where standardized. high-throughput assay would be preferred. For this purpose we developed the reverse FADU assay. The assay is fast. easy. fully automated. highly reproducible and of low cost. All these advantages make the reverse FADU an attractive candidate for large monitoring studies.
In the course of the present study. we optimized the assay conditions towards the highest resolution for the detection of ICL. The number of X-ray-induced DNA strand breaks to be administered in the reverse assay as well as unwinding conditions were systematically investigated and optimized resulting in development of the present protocol.
We were able to detect ICL in human PBMC after treatment with SM and two cytostatic drugs. i.e. mitomycin C and melphalan. SM was initially developed as a chemical warfare agent. Its last military use was during the Iraq-Iran war in the 1980s. However. accidental exposure of civilians is being reported even today. from the inappropriate disposal of sea-dumped ammunition or old depots. SM is a documented mutagen and carcinogen, and an increased tumour risk is caused even by low-dose exposure that does not evoke characteristic skin lesions (Balali-Mood and Hefazi, 2006) . Biomonitoring based on assessment of ICL is, therefore, an attractive option. This prompted us to include SM in the present study along with anticancer drugs. For all three substances we were able to detect ICL in a dose dependent manner. The dose response was assessed at the time point of maximal cross links induction for the respective substance, which we determined previously in time-course experiments. ICL were equally well detected independent on chemical structure. The assessment of ICL was possible for 5 /Lg/ml mitomycin C and melphalan, respectively. and 3 /LM SM. Based on the quantitative data available for SM (Mol et aI., 1993) , we estimated that the reverse FADU assay allows detection of 1 ICL per 4.2 x 10 6 bp, equivalent to approximately 780 crosslinks per genome.
The main question remains the sensitivity of the reverse FADU assay in comparison to other methods. The closest competitor is obviously the reverse comet assay. In our hands the sensitivity of the comet assay was comparable to that of the FADU assay. The minimal concentration for damage induction detectable by comet assay was 1 /LM SM. Melphalan induced crosslinks, however, were not detectable in the concentration range investigated. A similar relationship in sensitivity was obtained for comparison of FADU (15 /LM) with published data for mitomycin C (10 /LM) (Merk and Speit, 1999) . A major advantage of the reverse FADU assay over the comet assay is the absolutely stringent standardization of all steps in the protocol and read-out. Thus, our inter-assay variability is negligible and we expect the same to be the case for inter-laboratory variability. Due to the easy and fast procedure, which can be completed in 3 h, and the microtiter format used. the assay has a high throughput. It should therefore be very suitable for large cohort studies. Its applicability for clinical studies is currently under investigation. Furthermore. the reverse FADU assay is very promising for the biomonitoring of genotoxic exposure. Last but not least, in our hands the assay proved to be a useful tool for assessment of DNA damage and repair in cell culture experiments aimed at elucidation of molecular mechanisms.
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